CONTRATOS ARTICULO 60 LOSU
Contract
Experience In The Field of On Potential Indications of Molecules That Inhibit Nlrp3 And Potential Techniques To Use In The Design of Drugs That Inhibit Nlrp3.
Funder:
GLENMARK PHARMACEUTICALS LIMITED
date_range
Duration: from 22 April 2021 to 22 April 2022
(12 months)
euro
607.50 EUR
Of International (non-EU) scope. With a Private character.
Researchers
Pablo
Pelegrin Vivancos
Leader